A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to First-Line EGFR TKIs, Erlotinib or Gefitinib
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2015
Price : $35 *
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Jul 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 17 Jul 2014 New source identified and integrated (Vanderbilt-Ingram Cancer Center - VICCTHN1303).